Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pulmonary Safety of Staccato Loxapine for Inhalation in Subjects With Asthma

Next Previous
Trial Profile

Pulmonary Safety of Staccato Loxapine for Inhalation in Subjects With Asthma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Loxapine (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Alexza Pharmaceuticals

Most Recent Events

  • 11 Oct 2010 Valeant Pharmaceuticals have announced in a media release that the US FDA have said in a Complete Response Letter that they have a clinical safety concern related to data from this study and two other phase I pulmonary safety studies.
  • 02 Sep 2009 Planned number of patients changed from 50 to 52 as reported by ClinicalTrials.gov.
  • 29 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top